Proteus syndrome is an extremely rare genetic disorder that causes asymmetric, progressive overgrowth of bones, skin, fat, and blood vessels. It results from a spontaneous mutation that occurs randomly during early embryonic development and is not inherited from either parent. The condition gained public attention through its likely connection to Joseph Merrick, the Victorian-era “Elephant Man,” but the underlying biology wasn’t pinned down until 2011, when researchers identified the specific genetic change responsible. Because the mutation arises in only some of the body’s cells, no two people with Proteus syndrome look alike, and the severity can range from mild limb asymmetry to profoundly disfiguring overgrowth.
The Genetic Cause
Proteus syndrome traces back to a single letter change in the AKT1 gene, which encodes a protein involved in telling cells when to grow, divide, and survive. The mutation, designated c.49G→A (p.Glu17Lys), locks the AKT1 protein into an overactive state, so affected cells receive a constant “grow” signal regardless of normal cues from surrounding tissue.1PubMed Central. A mosaic activating mutation in AKT1 associated with the Proteus syndrome In the landmark study that identified the mutation, 26 of 29 patients tested positive for it, and the fraction of cells carrying the mutant gene varied widely, from as little as 1% to roughly 50%.2New England Journal of Medicine. A mosaic activating mutation in AKT1 associated with the Proteus syndrome
The word “somatic” is key here. The mutation is not present in egg or sperm cells; it pops up spontaneously after conception, while the embryo is still a tiny ball of dividing cells. From that point forward, every daughter cell of the affected cell carries the mutation, while the rest of the body does not. This patchwork is called mosaicism, and it explains why Proteus syndrome affects some body parts and spares others. Which tissues end up overgrown depends largely on when in development the mutation appeared and which cell lineage it landed in.
Researchers believe the mutation would be lethal if every cell in the body carried it. Mouse studies support this idea: when the Proteus-causing AKT1 variant was switched on throughout the entire embryo, the mice developed severe vascular defects and did not survive.3Human Molecular Genetics. Ubiquitous expression of Akt1 p.(E17K) results in vascular defects and embryonic lethality in mice That incompatibility with survival is precisely why the condition only appears in mosaic form. Rare cases have also been reported with other, novel AKT1 mutations, but the classic Glu17Lys change accounts for the vast majority of confirmed diagnoses.4PubMed Central. Proteus syndrome caused by novel somatic AKT1 duplication
How the Overgrowth Presents
Babies with Proteus syndrome usually look normal at birth. The overgrowth tends to begin in the first year or two of life and then accelerates during childhood, which is one of the hallmarks that separates this condition from other overgrowth disorders. The growth is disproportionate, asymmetric, and distorting: one leg may become dramatically longer and thicker than the other, individual fingers or toes can enlarge, and bony outgrowths may reshape the skull, spine, or limbs over time.5PubMed Central. Proteus syndrome: Clinical profile of six patients and review of literature Common skeletal findings also include vertebral abnormalities, hyperostosis (excessive bone growth), and significant limb-length discrepancy.6PubMed. Radiologic manifestations of Proteus syndrome
The feature most distinctive to Proteus syndrome is the cerebriform connective tissue nevus, a deeply ridged skin thickening that resembles the furrowed surface of a brain. It most often appears on the soles of the feet but can develop elsewhere. In children, these lesions tend to expand into previously uninvolved skin and grow thicker over time; in adults, the progression generally stabilizes.7PubMed Central. Progressive Overgrowth of the Cerebriform Connective Tissue Nevus in Patients with Proteus Syndrome Other skin and soft-tissue features can include epidermal nevi (raised, slightly rough patches that appear early in life), fatty tumors called lipomas, areas of underdeveloped fat, and vascular birthmarks of various types.8PubMed. Proteus syndrome review: molecular, clinical, and pathologic features
Because the mutation affects whichever tissue lineage it happened to land in, the overall picture varies enormously from person to person. Some people have mainly skeletal overgrowth. Others may have extensive vascular malformations with relatively modest bone involvement. This variability is what makes the disorder so challenging to recognize and manage.
Serious Complications
Beyond the visible overgrowth, Proteus syndrome carries real risks of internal complications that require ongoing monitoring.
Blood Clots
People with Proteus syndrome face an elevated risk of deep vein thrombosis and pulmonary embolism, a potentially life-threatening event in which a clot travels to the lungs.9PubMed Central. Proteus Syndrome: A Rare Case in An Adult Ward The reasons are likely several: large vascular malformations, reduced mobility due to skeletal deformities, the effects of surgery, and possible direct effects of the AKT1 mutation on blood vessel lining and platelet function.10PubMed Central. Characterization of thrombosis in patients with Proteus syndrome Pulmonary embolism is one of the leading causes of premature death in this population, so clinicians caring for these patients usually have a low threshold for preventive measures around surgery and periods of immobility.
Tumor Risk
The same overactive growth signaling that drives tissue overgrowth also predisposes to tumor development. A systematic review of clinical reports found that about 19% of people with Proteus syndrome developed at least one tumor, with the average age at diagnosis around 15 years. The most common tumor sites were the genitourinary and gynecologic organs, followed by the central nervous system. Encouragingly, most of these tumors were benign and treatable with surgery alone.11PubMed Central. Tumor spectrum in AKT1-related Proteus syndrome: A systematic review of clinical reports and series Specific tumor types reported include ovarian cystadenomas, parotid gland tumors, and meningiomas (tumors arising from the membranes surrounding the brain).12PubMed Central. Unilateral hypertrophic skin lesions, hemimegalencephaly, and meningioma: The many faces of Proteus syndrome
Lung Disease
Some individuals develop emphysematous and cystic changes in the lungs that can cause worsening breathing problems over time. These lung changes may require surgical intervention and represent another reason for regular imaging and follow-up.13PubMed Central. Quantification of Proteus syndrome-associated lung disease
Why Diagnosis Is Difficult
Proteus syndrome is thought to affect fewer than one in a million people worldwide. With a condition that rare, most physicians will never encounter a case, and there is a well-documented pattern of misdiagnosis. Many patients are initially labeled with other overgrowth conditions before the correct diagnosis is reached.
Researchers have long advocated for strict diagnostic criteria to keep the boundaries of Proteus syndrome clear. The clinical criteria require a combination of features that are considered general (sporadic occurrence, progressive course, asymmetric and disproportionate overgrowth) together with more specific findings, most critically the cerebriform connective tissue nevus.14PubMed. The challenges of Proteus syndrome: diagnosis and management Genetic testing for the AKT1 c.49G→A mutation can confirm the diagnosis, but there’s a catch: because the mutation is mosaic, a standard blood test may miss it entirely. The mutant cells may not be well represented in the blood. Testing needs to be done on affected tissue, and even then, the fraction of mutant cells can be very low, sometimes just a few percent. Sensitive sequencing methods are often necessary.
Conditions Commonly Confused With Proteus Syndrome
Several other disorders share overlapping features, and sorting them out matters for treatment and prognosis. The closest relative is a family of conditions called PIK3CA-Related Overgrowth Spectrum, or PROS. These conditions, which include CLOVES syndrome, are also caused by mutations in the same cellular growth pathway but involve a different gene, PIK3CA, rather than AKT1.15PubMed Central. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome CLOVES syndrome has historically been one of the most common misdiagnoses applied to people who actually have Proteus syndrome, and vice versa. A key distinguishing feature is that Proteus syndrome typically shows a normal appearance at birth with progressive distortion over time, whereas CLOVES tends to be present from birth.16DermNet. CLOVES syndrome
Neurofibromatosis type 1 is another condition that can be confused with Proteus syndrome, though the overlap is more superficial. Neurofibromatosis causes café-au-lait spots and nerve-sheath tumors, features that are not part of the Proteus picture. The distinction matters historically because the most famous case of likely Proteus syndrome was misdiagnosed as neurofibromatosis for nearly a century.
Joseph Merrick and the Elephant Man
Joseph Merrick was shown to the Pathological Society of London in 1884 by the surgeon Frederick Treves. His dramatic skeletal overgrowth, thickened skin, and subcutaneous masses made him one of the most studied medical cases of the Victorian era. A diagnosis of neurofibromatosis was proposed in 1909 and accepted for decades, but a 1986 re-evaluation pointed out that Merrick lacked the hallmark café-au-lait spots and had no histological evidence of neurofibromas. His features, including macrocephaly, hyperostosis of the skull, hypertrophy of long bones, thickened skin and subcutaneous tissue of the hands and feet, plantar hyperplasia, and lipomas, line up far more closely with Proteus syndrome.17PubMed Central. The Proteus syndrome: the Elephant Man diagnosed
The rediagnosis brought Proteus syndrome into the public spotlight, but it has also shaped misconceptions. Merrick’s case was unusually severe. Many people with Proteus syndrome have milder presentations, and the dramatic images associated with the Elephant Man can distort expectations of what the condition looks like in practice. Some researchers have also raised the possibility that Merrick may have had more than one condition simultaneously, though Proteus syndrome remains the best single explanation for his constellation of findings.
Orthopedic and Surgical Management
Because the overgrowth is progressive and asymmetric, orthopedic problems are central to the day-to-day reality of living with Proteus syndrome. Limb-length discrepancy can cause gait problems and secondary spinal curvature. Scoliosis from vertebral overgrowth is common and can be severe. Joint contractures develop when overgrown tissue limits range of motion. Management strategies include soft-tissue release procedures, early use of techniques to halt growth at specific growth plates, spinal bracing, and in some cases amputation when a limb becomes nonfunctional or dangerously overgrown.18PubMed Central. Assessment and management of the orthopedic and other complications of Proteus syndrome
These decisions are rarely straightforward. The overgrowth can recur after surgery, tissue is often abnormal in ways that complicate wound healing, and the mosaic distribution of affected tissue means surgeons cannot always predict how a given area will behave postoperatively. A multidisciplinary team that includes orthopedic surgeons, dermatologists, vascular specialists, and geneticists is considered essential for coordinating care.19PubMed Central. Proteus Syndrome: a difficult diagnosis and management plan
Pain and Quality of Life
Pain is an underappreciated part of Proteus syndrome. Vertebral overgrowth causing scoliosis and spinal stenosis can produce chronic, debilitating back pain. A case report of a 35-year-old man with severe scoliosis and vertebral overgrowth described the successful use of spinal joint injections to manage his ongoing pain, illustrating that interventional pain techniques can be a valuable tool alongside surgical approaches.20PubMed Central. The Role of Interventional Pain Management in Proteus Syndrome: A Case Report Bone overgrowth can also impinge on nerves, and the sheer mechanical stress of carrying asymmetrically enlarged limbs creates chronic musculoskeletal strain.
The psychological burden is substantial as well, though harder to quantify. Visible disfigurement, physical limitations, repeated surgeries from childhood onward, and the rarity of the condition (meaning few peers who share the experience) all contribute. Psychological support and connections to patient advocacy organizations are routinely recommended as part of comprehensive care, though published research specifically studying mental health outcomes in Proteus syndrome remains sparse.
Targeted Therapy With Miransertib
For decades, treatment for Proteus syndrome was entirely reactive: surgery to remove overgrown tissue, bracing to manage skeletal deformity, and monitoring for complications. The identification of the AKT1 mutation opened the door to a fundamentally different strategy: blocking the overactive protein itself.
Miransertib (originally called ARQ 092) is a drug designed to inhibit AKT signaling. In laboratory studies, it reduced the elevated AKT activity in cells taken from Proteus syndrome patients.21Scientific Reports. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome A pharmacodynamic study in six individuals with Proteus syndrome found that a low dose, roughly one-seventh of the dose typically used in cancer treatment, achieved about a 50% reduction in active AKT in affected tissues and was well tolerated. Two measures hinted at real clinical benefit: a decrease in the cerebriform connective tissue nevus and a reduction in pain in children.22PubMed Central. Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
A separate case report described one patient treated with miransertib for 11 months who reported improved overall well-being, better mobility in the ankle, spine, and hands, a subjective decrease in facial bone overgrowth, and reduced cerebriform connective tissue nevi on the soles. MRI showed stable disease without apparent progression.23PubMed Central. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092) These are early results from small numbers of patients, not the kind of large trials that produce definitive answers. But for a condition with no prior disease-modifying treatment, stabilization and symptomatic improvement count as meaningful progress. Larger efficacy trials are ongoing.
Mouse Models and Research Directions
Progress in understanding Proteus syndrome has been constrained by its rarity. With so few patients worldwide, large clinical studies are nearly impossible. Mouse models have helped fill the gap. Researchers have engineered mice with mosaic expression of the same AKT1 variant found in human patients, allowing the mutation to turn on randomly in some cells while leaving others normal, mimicking the human mosaic pattern.24PubMed Central. A mouse model of Proteus syndrome These animals develop overgrowth features and have become a platform for testing potential therapies before they reach human trials.
The existence of a validated animal model, combined with the fact that the molecular target is known with unusual precision, puts Proteus syndrome in a relatively favorable position compared to many rare diseases. The AKT pathway is already the subject of extensive cancer research, which means a pipeline of AKT-inhibiting drugs exists. The challenge lies in adapting those drugs for a chronic, lifelong condition in children, where long-term safety is paramount and the goal is not tumor shrinkage but prevention of progressive overgrowth. How early treatment needs to start, how long it needs to continue, and whether it can reverse existing overgrowth rather than simply halt further progression are among the open questions researchers are working to answer.